321 related articles for article (PubMed ID: 33957868)
41. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
Tolley K; Oliver N; Miranda E; Migliaccio-Walle K; Bozkaya D; Li Q
J Med Econ; 2010; 13(3):559-70. PubMed ID: 20812793
[TBL] [Abstract][Full Text] [Related]
42. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
Delforge M; Selleslag D; Beguin Y; Triffet A; Mineur P; Theunissen K; Graux C; Trullemans F; Boulet D; Van Eygen K; Noens L; Van Steenweghen S; Lemmens J; Pierre P; D'hondt R; Ferrant A; Deeren D; Van De Velde A; Wynendaele W; André M; De Bock R; Efira A; Breems D; Deweweire A; Geldhof K; Pluymers W; Harrington A; MacDonald K; Abraham I; Ravoet C
Leuk Res; 2014 May; 38(5):557-63. PubMed ID: 24661630
[TBL] [Abstract][Full Text] [Related]
43. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
Kaplan HG; Malmgren JA; Atwood MK
BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
[TBL] [Abstract][Full Text] [Related]
44. Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes.
Carreau N; Tremblay D; Savona M; Kremyanskaya M; Mascarenhas J
Blood Rev; 2016 Sep; 30(5):349-56. PubMed ID: 27106071
[TBL] [Abstract][Full Text] [Related]
45. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
46. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.
Steensma DP
Curr Hematol Malig Rep; 2011 Jun; 6(2):136-44. PubMed ID: 21373838
[TBL] [Abstract][Full Text] [Related]
47. New insights into transfusion-related iron toxicity: Implications for the oncologist.
Porter JB; de Witte T; Cappellini MD; Gattermann N
Crit Rev Oncol Hematol; 2016 Mar; 99():261-71. PubMed ID: 26806144
[TBL] [Abstract][Full Text] [Related]
48. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Hoeks M; Yu G; Langemeijer S; Crouch S; de Swart L; Fenaux P; Symeonidis A; Čermák J; Hellström-Lindberg E; Sanz G; Stauder R; Holm MS; Mittelman M; Mądry K; Malcovati L; Tatic A; Almeida AM; Germing U; Savic A; Šimec NG; Culligan D; Itzykson R; Guerci-Bresler A; Slama B; Droste J; van Marrewijk C; van de Loosdrecht A; Blijlevens N; van Kraaij M; Bowen D; de Witte T; Smith A;
Haematologica; 2020 Mar; 105(3):640-651. PubMed ID: 31278207
[TBL] [Abstract][Full Text] [Related]
49. Deferasirox for managing iron overload in people with myelodysplastic syndrome.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2010 Nov; (11):CD007461. PubMed ID: 21069694
[TBL] [Abstract][Full Text] [Related]
50. Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.
Calabrese C; Panuzzo C; Stanga S; Andreani G; Ravera S; Maglione A; Pironi L; Petiti J; Shahzad Ali MS; Scaravaglio P; Napoli F; Fava C; De Gobbi M; Frassoni F; Saglio G; Bracco E; Pergolizzi B; Cilloni D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081324
[TBL] [Abstract][Full Text] [Related]
51. Transfusion-related Iron Overload in Children With Leukemia.
Cacciotti C; Athale U
J Pediatr Hematol Oncol; 2021 Jan; 43(1):18-23. PubMed ID: 32487848
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of deferasirox in myelodysplastic syndromes.
Breccia M; Alimena G
Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
[TBL] [Abstract][Full Text] [Related]
53. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.
Leitch HA; Chan C; Leger CS; Foltz LM; Ramadan KM; Vickars LM
Leuk Res; 2012 Nov; 36(11):1380-6. PubMed ID: 22921191
[TBL] [Abstract][Full Text] [Related]
54. A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
Kennedy GA; Morris KL; Subramonpillai E; Curley C; Butler J; Durrant S
Br J Haematol; 2013 Jun; 161(6):794-801. PubMed ID: 23590671
[TBL] [Abstract][Full Text] [Related]
55. Iron overload in myelodysplastic syndromes (MDS).
Gattermann N
Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
[TBL] [Abstract][Full Text] [Related]
56. Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34
Shapira S; Raanani P; Samara A; Nagler A; Lubin I; Arber N; Granot G
Exp Hematol; 2019 Feb; 70():55-69.e4. PubMed ID: 30414989
[TBL] [Abstract][Full Text] [Related]
57. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
Angelucci E; Cianciulli P; Finelli C; Mecucci C; Voso MT; Tura S
Leuk Res; 2017 Nov; 62():108-115. PubMed ID: 29054020
[TBL] [Abstract][Full Text] [Related]
58. Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of FOS.
Yang F; Cui X; Wang H; Zhang D; Luo S; Li Y; Dai Y; Yang D; Zhang X; Wang L; Zheng G; Zhang X
Cancer Lett; 2024 Feb; 583():216652. PubMed ID: 38242196
[TBL] [Abstract][Full Text] [Related]
59. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
60. Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy.
Wong CAC; Leitch HA
Leuk Res; 2019 Aug; 83():106170. PubMed ID: 31229803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
